Health and Healthcare
Savient (SVNT) Rises 55% On Bad News
Published:
Last Updated:
Shares in pharma firm Savient (SVNT) are up 55% to $9.13 on what would appear to be very bad news. The FDA issued a statement saying it has safety concerns about the company’s gout drug.
According to the agency, side effects of the drug Krystexxa include sudden death from heart attack and allergic reactions. The silver lining is that the treatment may actually be approved. The FDA commented that it does “does not dispute the efficacy” of the drug.
Reuters reports that“Savient, in a separate document also released on Friday, said the drug was important for patients who have no other options and that it “can be successfully managed with careful clinical monitoring.”
Apparently patient heart attacks are good for the company’s shareholders.
Douglas A. McIntyre
Take Charge of Your Retirement: Find the Right Financial Advisor For You in Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding professional guidance—and we’ve made it easier than ever for you to connect with the right financial advisor for your unique needs.
Here’s how it works:
1️ Answer a Few Simple Questions
Tell us a bit about your goals and preferences—it only takes a few minutes!
2️ Get Your Top Advisor Matches
This tool matches you with qualified advisors who specialize in helping people like you achieve financial success.
3️ Choose Your Best Fit
Review their profiles, schedule an introductory meeting, and select the advisor who feels right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.